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1,3a,6a-Triazapentalene is a compact fluorescent chromophore. In this study, triazapentalene was used 
to modify a series of biphenyl-type inhibitors of kinesin spindle protein (KSP) to develop fluorescent 
probes for the intracellular visualization of this protein. Microscopic studies demonstrated that these 
novel triazapentalene-labeled compounds exhibited inhibitory activity towards KSP in cultured cells 
and provided important information concerning the intracellular distribution. 
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1,3a,6a-Triazapentalene 1 is a fluorescent chromophore with a high quantum yield (Figure 1).1 This 
simple bicyclic heterocycle has been used to develop a variety of fluorescent dyes by the modification 
of its core structure at its 2-, 4- and 5-positions with a variety of different groups.2 Cai’s group reported 
the use of a gold-catalyzed triazole-alkyne cyclization to give a series of 1,3a,6a-triazapentalene 
derivatives.3 To date, two triazapentalene derivatives have been employed to investigate changes in 
the morphological characteristics of cells.2b,4 2-[2-Cyano-4-(methoxycarbonyl)phenyl]triazapentalene 
1b was the first fluorescent probe to be shown to accumulate in the cytoplasm.2b 2-(Biphenyl-4-
yl)triazapentalene 1c, which is also known as TAP-4PH, has been used as a fluorescence imaging probe 
to visualize neuronal and neutrophilic differentiation processes in PC-12 and HL-60 cells, 
respectively.4 We envisaged that this unique triazapentalene structure could be used as a 
pharmacophore functional group and incorporated into the aromatic heterocyclic scaffolds of novel 
drug candidates in medicinal chemistry to visualize their targets. The modification of the core 
structures of biomolecules and bioactive substances with this tiny triazapentalene scaffold could be 
used as a general strategy to allow for the fluorescent labeling of these compounds without any 
discernible loss in their original bioactivity. This approach would therefore provide favorable 
fluorescent probes for visualizing the distribution of bioactive substances, as well as the distribution 




Figure 1. Structures of 1,3a,6a-triazapentalene 1a and the application of this group to the development 
of fluorescent probes 1b and 1c for probing morphological changes in cells. 
 
 
Several research groups, including our own, have recently reported the development of kinesin 
spindle protein (KSP) inhibitors with potent antiproliferative activities (Figure 2). For example, 
substituted biphenyl derivatives 2 are unique KSP inhibitors. Notably, these compounds have been 
reported to exhibit potent activity against mutant KSP proteins, which are resistant to the allosteric 
KSP inhibitor, ispinesib.6 Several 2,3-fused indole structures, including carbazoles and b-carbolines, 
which are often observed in cytotoxic natural products, have been reported as effective alternatives to 
the traditional scaffolds describled above for the preparation of KSP inhibitors.7 Carbazole derivatives 
bearing different substituents at specific positions on their ring exhibited highly potent inhibitory 
activity towards KSP, as well as cytotoxicity towards human cance cells.8 Diarylamine-type inhibitors 
of KSP have also been designed to improve the aqueous solubility of fused indole-type KSP inhibitors.9 
The modification of these structures with a nonplanar cyclic moiety or a charged heterocyclic system 
afforded a novel series of potent KSP inhibitors with favorable physicochemical properties.10 These 
molecules bearing simple aromatic scaffolds inhibited the microtubule-activated ATPase activity of 
the motor domain of KSP in an apparent ATP-competitive manner. 	  
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Figure 2. Design of novel KSP probes based on the structures of fluorescent 1,3a,6a-triazapentalene 
scaffold and biaryl-type KSP inhibitors. 
 
 
KSP inhibitors inhibit the mitotic progression of the cell cycle, resulting in the accumulation of 
mitotic cells by suppressing the movement of centrosomes, which is required for the formation of 
bipolar spindles during early mitosis.11 The results of phenotypic studies involving mitotic cells 
arrested by biphenyl-type inhibitors demonstrated that the monoastral phenotype appeared to be similar 
to that achieved using allosteric inhibitors such as monastrol and S-trityl-cysteine (STLC). However, 
the intracellular distribution patterns of KSP as well as the binding sites on KSP were completely 
different in these two cases.6c,6d In addition, considerable differences were observed in the in vitro 
biochemical activities of biphenyl-type KSP inhibitors and their activities in cultured cell assays, which 
were supported by our structure-activity relationship studies.6c Indeed, some of biphenyl derivatives 
inhibited the proliferation of cells without causing cell cycle arrest at the mitosis stage, even though 
they showed good inhibitory activity against the ATPase activity of KSP in vitro. In this study, we have 
investigated the intracellular distribution of a biphenyl-type KSP inhibitor using a novel fluorescent 
probe. This study represents the first reported application of a 1,3a,6a-triazapentalene moiety as a 
bifunctional substructure with fluorescent and pharmacophoric properties for the visualization of 
bioactive substances and their targets. 
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The modification of a small molecule with a fluorescent probe or some other functional group often 
prevents the binding of the small molecule to the target molecule(s), leading to changes in the 
localization of the compound. To minimize the possibility of introducing an interactive functional 
group that could interfere with the biological activity of the parent molecule, we designed two different 
KSP inhibitors 3 and 4. In these cases, a fluorescent 1,3a,6a-triazapentalene moiety was used as a 
phenyl surrogate and/or a terminal pharmacophore group to give two fluorescently-labeled biphenyl-
type KSP inhibitors (Figure 2). Compounds 3 and 4 were synthesized according to our previously 
reported procedures (Scheme 1).1 Briefly, alkyne 6 was directly converted to the target 4-
(trifluoromethyl)phenyl derivative 3 via the formation of the Huisgen cycloaddition product A, 
followed by an aromatization process. The biphenyl-type congener 4 was obtained in a similar manner 
from alkyne 8, which was prepared by the Sonogashira coupling of 7 with TMS-acetylene followed 
by the removal of the TMS protecting group. 
 
Scheme 1. Synthesis of the novel fluorescent KSP probes 3 and 4 bearing a 1,3a,6a-triazapentalene 
scaffold. Reagents and conditions: (a) CuI (5 mol %), (Me2NCH2CH2)2O (5 mol %), Et3N (5 equiv), 
THF (0.01 M), rt; (b) Trimethylsilylacetylene, CuI, Pd(PPh3)4, Et2N, DMF, 80 °C; (c) TBAF, THF, rt; 
(d) 5, CuI (5 mol %), (Me2NCH2CH2)2O (5 mol %), Et3N (5 equiv), THF (0.01 M), rt. 
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With the two triazapentalene derivatives (3 and 4) in hand, we proceeded to investigate their 
fluorescence properties in dichloromethane (Figure 3). The absorption spectra of compounds 3 and 4 
contained characteristic absorption bands from 300 to 400 nm, with absorption maxima (labs) at 357 
nm. The emission wavelengths (lem) of compounds 3 and 4 were determined to be 466 and 506 nm, 
respectively, making them suitable for fluorescence microscopy analysis in cellular systems. These 
compounds also exhibited large Stokes shifts and high fluorescence quantum yields (FF), which are 
favorable for excluding background signals. 
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The inhibitory activities of compounds 3 and 4 against the microtubule-activated ATPase activity 
of KSP were determined using an in vitro ATPase assay. Compound 3 moderately inhibited the ATPase 
activity (34% inhibition at 20 µM). Compound 4 gave an IC50 value of 6.8 µM (Table 1), which 
suggested that the introduction of a fluorescent triazapentalene moiety in 4 had a modest impact on the 
inhibitory activities of the parent compounds. Compounds 3 and 4 were subsequently examined for 
their anti-proliferative activity in HeLa human cervical adenocarcinoma cells and A549 lung 
adenocarcinoma cells using a growth inhibition assay. Compounds 3 and 4 gave GI50 values of 25 and 
19 µM in HeLa cells, respectively (Table 1). In terms of their activity against A549 cells, compound 3 
was much less potent than 4 [GI50(4) = 22 µM]. These results suggested that both of these compounds 
were less potent than the parent inhibitor PVZB1194 (2c).6c Compound 4 was determined to be the 
most potent of the two compounds prepared in this study and was therefore selected for further 
evaluation in cells. To determine whether compound 4 could inhibit mitotic progression in cultured 
cells, we added it to synchronized HeLa cells as they entered the M phase of the cell cycle. The cells 
were then cultured for 4 h at 37 °C before being fixed and visualized by immunofluorescence. 
Microscopic observations revealed that there was a concentration-dependent accumulation of mitotic 
cells, with a concentration of 40 µM of 4 being particularly effective for inhibiting the division of these 
cells (Figure 4A). The reduction in mitotic index at 50 µM of 4 resulted from its poor solubility in the 
medium, as microscopic observations found the deposition of insoluble 4 at concentrations above 50 
µM. The narrow window for the effective concentrations was attributed to the poor solubility and the 
moderate inhibitory activity of compound 4 against the ATPase activity of KSP. The major phenotype 
of the cells arrested in the M phase by 40 µM of 4 was prometaphase with monopolar spindles (63% 
of the mitotic cells), which is consistent with the phenotype induced by KSP inhibitors (Figure 4B).6c 
The KSP inhibitory activity of 4 was also supported by the unique and irregular accumulation of KSP 
in the central region of the mitotic cells, which is consistent with the intracellular localization induced 
by other biphenyl-type KSP inhibitors (Figure 4C).6c These results therefore indicated that compound 













3 >20d 25 ± 0.7 >30e 
 
4 6.8 ± 2.8 19 ± 0.5 22 ± 5.8 
aInhibition of microtubule-activated ATPase activity of KSP. bIC50 values were calculated from three 
independent experiments. cThe data were obtained from at least three independent experiments by the 
MTS assay. d34% inhibition at 20 µM. e6% cell growth inhibition at 30 µM. 
 
Figure 4. Potential KSP inhibitory activity of compound 4 in cultured cells. (A) Compound 4 
attenuated the mitotic progression of HeLa cells in a concentration-dependent manner. The average 
relative mitotic indices of two independent experiments are shown (see Supplementary experimental 
procedure). (B and C) Fluorescent microscopy images of HeLa cells treated with 40 µM of 4. After 
incubating synchronized cells with 4 for 4 h, the cells were fixed and immunostained. The arrows in 
(B) indicate the prometaphase cells with monopolar spindles. Two representative examples of the 
monoastral mitotic cells are shown in (C). Red, cyan and green signals were obtained using an anti-α-
tubulin antibody, DAPI (4’,6-diamidino-2-phenylindole) and an anti-KSP antibody, which showed 
microtubules, chromosomes and KSP, respectively. The right panels in (C) show the merged images 
of these colors. Notably, compound 4 was washed out during the immunostaining procedure. 
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HeLa cells expressing α-tubulin or histone H2B, which were conjugated with hmAG1 fluorescent 
proteins as organelle specific markers of the cytoplasm and nucleus, respectively, were used to 
investigate the intracellular distribution of compound 4.12 The cells were incubated with 4 for 20 min 
at 37 °C to prior to visualizing its localization. Live cell imaging using fluorescent microscopy showed 
that compound 4 gave a much stronger fluorescent signal inside the cells than it did outside the cells 
(Figure 5A). This efficient uptake of 4 into the cells suggested that the triazapentalene fluorophore had 
not had an adverse impact on the membrane permeability of this compound. The fluorescent signals 
of 4 were mainly localized in the cytoplasm of the interphase cells, where KSP localizes during the 
interphase, rather than in the nucleus.11 
To further determine the intracellular destination of 4, we used HeLa cells stably expressing KSP 
conjugated to a hmAG1 fluorescent protein at its N-terminus. This fluorescent KSP recombinant 
protein localized in the same way as the endogenous protein through mitosis and cytokinesis without 
affecting the cell cycle process (Figure 5C).11 Compound 4 (40 µM) was incubated with mitotic cells 
for 20 min at 37 °C to visualize its localization. In the monoastral mitotic cells induced by compound 
4, some of the fluorescence associated with this compound overlapped with the central localization of 
KSP (Figure 5B). In contrast, as it was in the cells treated with 20 µM of 4, we did not observe any 
inhibition of mitosis in these cells, and the fluorescence of 4 did not accumulate where KSP localized 
through the mitotic phases (Figure 4A and 5C). However, the fluorescence of 4 appeared to overlap 
well with the localization of KSP in the G2 and early mitotic phases (Figure 5C). This result indicated 
that compound 4 would exhibit desirable localization properties in the situations where KSP was 
contributing to centrosomal movement to establish a bipolar structure during the early mitotic phases. 
These data therefore demonstrate that compound 4 labeled mitotic KSP with partial specificity in 
cultured cells. The sub-localization of 4 in the cellular region devoid of KSP suggests that possible 
unexpected side-effects of 4 could be attributed to alternative intracellular sites of action.13 	  
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Figure 5. Fluorescent microscopy images of HeLa cells stained with compound 4. (A) HeLa cells 
expressing fluorescent α-tubulin or fluorescent histone H2B were treated with 20 µM of probe 4 for 
20 min. (B and C) Mitotic HeLa cells expressing fluorescent KSP were treated with 40 µM (B) or 20 
µM (C) of probe 4 for 20 min. Fluorescent images of cells with the monoastral phenotype (B) and 
normal mitotic phases (C). Compound 4 and the fluorescent proteins are shown in cyan and red, 
respectively. The cells were classified into each mitotic phase by visual inspection to determine the 
localization of their intracellular KSP. 
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In summary, we have designed and synthesized two novel fluorescently-labeled KSP inhibitors 3 
and 4 using a 1,3a,6a-triazapentalene scaffold. The dual pharmacophore and fluorophore functions of 
the 1,3a,6a-triazapentalene moiety did not have an adverse impact on the KSP inhibitory activities of 
the parent biphenyl-type inhibitors. Microscopic imaging studies revealed not only the intracellular 
distribution profile of 4, but also the partial colocalization of 4 with KSP, suggesting that the biphenyl 
derivative 4 could potentially be used as a small-molecule fluorescent probe for KSP. Compound 4 
was also observed in areas of the cell where there is no KSP, suggesting that there could be secondary 
target(s) for this biphenyl-type system, which could explain some of its side effects. Taken together, 
the results of this study provide a good example of the compatibility between the bioactivity and 
intracellular distribution of small-molecule inhibitors. Further studies towards the potential application 
of this 1,3a,6a-triazapentalene fluorophore for analyzing the mechanisms of action of different drugs 
and visualizing their target proteins are currently in progress in our laboratory. 
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